Evaluation of efficacy and safety of targeted therapy and immune checkpoint inhibitors in metastatic colorectal cancer

Figure 1 Flowchart illustrating the patient selection process for the study. PSM: Propensity score matching; IPW: Inverse probability weighting; ICI: Immune checkpoint inhibitor.

Figure 2 Kaplan-Meier survival curves comparing targeted therapy and targeted therapy + immune checkpoint inhibitor (targeted therapy combined with immune checkpoint inhibitors). A and B: Original data: Progression-free survival (PFS; A) and overall survival (OS; B); C and D: Propensity score matching: PFS (C) and OS (D); E and F: Inverse probability weighting: PFS (E) and OS (F). Log-rank test P values are indicated on each panel. The number at risk at different time points is shown below the X-axis. TT: Targeted therapy; ICI: Immune checkpoint inhibitor.

Figure 3 Subgroup analysis of progression-free survival in metastatic colorectal cancer patients. A: Univariate subgroup analysis; B: Multifactorial subgroup analysis. TT: Targeted therapy; ICI: Immune checkpoint inhibitor; HR: Hazard ratio; 95%CI: 95% confidence interval; LM: Liver metastasis; LuM: Lung metastasis; PM: Peritoneal metastasis; OM: Other metastases.